Journey Medical (DERM) Competitors

Journey Medical (NASDAQ:DERM) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, community ranking, institutional ownership and valuation.

Does the media prefer DERM or TRVI?

In the previous week, Trevi Therapeutics had 2 more articles in the media than Journey Medical. MarketBeat recorded 5 mentions for Trevi Therapeutics and 3 mentions for Journey Medical. Trevi Therapeutics' average media sentiment score of 1.42 beat Journey Medical's score of 0.76 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer DERM or TRVI?

Journey Medical presently has a consensus price target of $9.88, indicating a potential upside of 33.09%. Trevi Therapeutics has a consensus price target of $17.56, indicating a potential upside of 154.16%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Trevi Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Trevi Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.30

Is DERM or TRVI more profitable?

Trevi Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -31.74%. Trevi Therapeutics' return on equity of -63.31% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-31.74%	-132.10%	-26.90%
Trevi Therapeutics	N/A	-63.31%	-57.06%

Does the MarketBeat Community favor DERM or TRVI?

Trevi Therapeutics received 100 more outperform votes than Journey Medical when rated by MarketBeat users. However, 85.71% of users gave Journey Medical an outperform vote while only 67.95% of users gave Trevi Therapeutics an outperform vote.

Company	Underperform	Outperform
Journey Medical	Outperform Votes 6 85.71%	Underperform Votes 1 14.29%
Trevi Therapeutics	Outperform Votes 106 67.95%	Underperform Votes 50 32.05%

Which has more volatility and risk, DERM or TRVI?

Journey Medical has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Which has stronger earnings & valuation, DERM or TRVI?

Journey Medical has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Journey Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$56.13M	3.05	-$3.85M	-$0.74	-10.03
Trevi Therapeutics	N/A	N/A	-$29.07M	-$0.47	-14.70

Do institutionals and insiders hold more shares of DERM or TRVI?

7.3% of Journey Medical shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 13.2% of Journey Medical shares are held by insiders. Comparatively, 24.4% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Trevi Therapeutics beats Journey Medical on 12 of the 18 factors compared between the two stocks.